P-094KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study. (2nd July 2019) - Chung, H; Bang, Y; Fuchs, C; Qin, S; Satoh, T; Shitara, K; Tabernero, J; Van Cutsem, E; Cao, Z; Chen, X; Kang, S; Shih, C; et al.